ArticleMacromolecular bioscience2026
In Vivo Evaluation of Injected and Bioprinted Hyaluronic Acid-Based Bioink in Corneal Stromal Pocket.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- In Vivo Evaluation of Injected and Bioprinted Hyaluronic Acid-Based Bioink in Corneal Stromal Pocket.Macromolecular bioscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The corneal stroma contains specialized stromal keratocytes (CSKs) that preserve corneal transparency and homogeneity. Stromal scarring and opacities lead to vision loss in millions globally. While corneal transplantation remains the gold standard, it is constrained by donor shortages. Cell-based therapies using primary stromal cells show promise but still depend on donor tissue. Human adipose tissue-derived stem cells (hASCs) offer an abundant alternative, capable of differentiating into CSKs. A three-dimensional (3D) tissue matrix is essential for mimicking native tissue and supporting stromal regeneration. Hyaluronic acid (HA)-based matrices emerge as promising stromal substitutes. In this study, we aim to investigate the biocompatibility of HA-based bioink, both as injectable formulations and bioprinted constructs containing hASC-CSKs. In vitro, bioprinted HA-based constructs containing hASC-CSKs exhibit high cell viability, an organized structure, and maintained transparency. In vivo, the bioink integrates progressively into the corneal stroma, considerably reducing stromal thickness within two weeks. It supports the hASC-CSK phenotype post-transplantation, as indicated by lumican expression. Although inflammatory responses are observed, the bioink shields transplanted cells from immune rejection, promoting graft survival and integration. These findings demonstrate that HA-based bioink serves as a biocompatible scaffold for cell delivery, supporting stromal regeneration and highlighting its potential for future corneal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.